scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lowered its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 18.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 135,080 shares of the company’s stock after selling 31,136 shares during the period. Dimensional Fund Advisors LP owned 0.37% of scPharmaceuticals worth $588,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of SCPH. Thomasville National Bank lifted its position in scPharmaceuticals by 11.5% in the first quarter. Thomasville National Bank now owns 36,800 shares of the company’s stock valued at $185,000 after acquiring an additional 3,800 shares during the last quarter. Balanced Rock Investment Advisors LLC lifted its position in scPharmaceuticals by 9.2% in the first quarter. Balanced Rock Investment Advisors LLC now owns 57,248 shares of the company’s stock valued at $287,000 after acquiring an additional 4,827 shares during the last quarter. Perkins Capital Management Inc. purchased a new stake in scPharmaceuticals in the first quarter valued at $53,000. Bank of New York Mellon Corp lifted its position in scPharmaceuticals by 15.1% in the second quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company’s stock valued at $375,000 after acquiring an additional 11,269 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in scPharmaceuticals in the first quarter valued at $90,000. Institutional investors and hedge funds own 89.52% of the company’s stock.

scPharmaceuticals Trading Up 3.7 %

Shares of scPharmaceuticals stock opened at $4.23 on Monday. scPharmaceuticals Inc. has a 12-month low of $3.24 and a 12-month high of $6.71. The company has a current ratio of 4.84, a quick ratio of 3.66 and a debt-to-equity ratio of 4.32. The stock has a market cap of $211.63 million, a PE ratio of -2.71 and a beta of 0.13. The company has a 50-day moving average of $4.82 and a two-hundred day moving average of $4.58.

scPharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.44) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.44). The business had revenue of $8.05 million during the quarter, compared to analysts’ expectations of $8.04 million. scPharmaceuticals had a negative net margin of 252.18% and a negative return on equity of 201.84%. On average, research analysts anticipate that scPharmaceuticals Inc. will post -1.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of scPharmaceuticals in a research note on Monday, August 19th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.